Gut microbiota-ferroptosis signaling as a putative feed-forward amplifier of pulmonary immunometabolic reprogramming in acute respiratory distress syndrome: actionable therapeutic targets

Acute respiratory distress syndrome (ARDS) is characterized by dysregulated pulmonary immune responses, and effective targeted therapeutic strategies remain an unmet clinical need. Accumulating preclinical and clinical correlative data reveal complex interconnections between gut microbiota and ferroptosis-driven immunopathology in ARDS, yet an integrated mechanistic understanding of the gut-lung pathological axis remains incomplete. This review puts forward a testable conceptual temporal framework for ARDS-related gut-lung crosstalk. Evidence supporting the gut-to-lung limb is comparatively more abundant, whereas the full sequential pathogenic cascade has not been rigorously validated. Gut-derived metabolites remodel pulmonary cell phenotypes, macrophage functional states, neutrophil extracellular trap formation and T-cell homeostasis, potentially sustaining a self-amplifying ferroptosis-inflammatory vicious cycle that may drive pulmonary immunometabolic reprogramming. Targeting this regulatory cascade may yield promising conceptual therapeutic avenues, including microbiota-modulating interventions, anti-ferroptotic strategies and multi-omics-guided precision approaches. Major knowledge gaps persist: most mechanistic observations are extrapolated from non-ARDS animal models; temporally-separated preclinical experiments that induce lung injury prior to gut-targeted manipulation are scarce; and well-controlled human studies disentangling pulmonary-driven effects from ICU confounders are urgently required. This sequence represents an etiology-dependent working model rather than a uniform chronological hierarchy for all ARDS. In direct-pulmonary ARDS, alveolar injury may precede gut dysbiosis; in indirect/sepsis-associated ARDS, systemic inflammation, intestinal hypoperfusion and antibiotic exposure may occur before, or simultaneously with, overt pulmonary ferroptotic injury.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-10-28
DOI
https://doi.org/10.3389/fimmu.2026.1900118
Primary Topic
Gut microbiota and health
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Gut microbiota-ferroptosis signaling as a putative feed-forward amplifier of pulmonary immunometabolic reprogramming in acute respiratory distress syndrome: actionable therapeutic targets

Lihua Liao, 张东伟, Xianming Fan, Weitong Zeng et al.
4 links
Frontiers in Immunology
Gut microbiota and health
article

Gut microbiota-ferroptosis signaling as a putative feed-forward amplifier of pulmonary immunometabolic reprogramming in acute respiratory distress syndrome: actionable therapeutic targets

Lihua Liao, 张东伟, Xianming Fan, Weitong Zeng, Bing Zhong, Yi Wei, Biying Dong, Longxiong Liao
article en

Abstract

Acute respiratory distress syndrome (ARDS) is characterized by dysregulated pulmonary immune responses, and effective targeted therapeutic strategies remain an unmet clinical need. Accumulating preclinical and clinical correlative data reveal complex interconnections between gut microbiota and ferroptosis-driven immunopathology in ARDS, yet an integrated mechanistic understanding of the gut-lung pathological axis remains incomplete. This review puts forward a testable conceptual temporal framework for ARDS-related gut-lung crosstalk. Evidence supporting the gut-to-lung limb is comparatively more abundant, whereas the full sequential pathogenic cascade has not been rigorously validated. Gut-derived metabolites remodel pulmonary cell phenotypes, macrophage functional states, neutrophil extracellular trap formation and T-cell homeostasis, potentially sustaining a self-amplifying ferroptosis-inflammatory vicious cycle that may drive pulmonary immunometabolic reprogramming. Targeting this regulatory cascade may yield promising conceptual therapeutic avenues, including microbiota-modulating interventions, anti-ferroptotic strategies and multi-omics-guided precision approaches. Major knowledge gaps persist: most mechanistic observations are extrapolated from non-ARDS animal models; temporally-separated preclinical experiments that induce lung injury prior to gut-targeted manipulation are scarce; and well-controlled human studies disentangling pulmonary-driven effects from ICU confounders are urgently required. This sequence represents an etiology-dependent working model rather than a uniform chronological hierarchy for all ARDS. In direct-pulmonary ARDS, alveolar injury may precede gut dysbiosis; in indirect/sepsis-associated ARDS, systemic inflammation, intestinal hypoperfusion and antibiotic exposure may occur before, or simultaneously with, overt pulmonary ferroptotic injury.

Frontiers in ImmunologyVol. 17
Guangxi Medical University (CN), Affiliated Hospital of Southwest Medical University (CN)
Southwest Medical University
Good health and well-being
Openalex Percentile: Top 23%
Gut microbiota and health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon